Abrocitinib,Dupilumab
pfizer,sanofi,regeneron
['derm', 'vitiligo', 'pfizer']
at #eadvcongress, we re sharing updates from a phase 3 study evaluating the efficacy of our jak inhibitor in #atopicdermatitis (ad), along with real world data in ad and data on #vitiligo. #pfizermedical
Communicating emerging, trusted scientific information to healthcare professionals (HCPs). Pfizer sponsored, intended for U.S. HCPs. https://t.co/s5bPfuTvDc